Skip to main content

Table 2 Treatment characteristics

From: A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria

Authors Diagnostics Parasitaemia Drug Dosing (total) Period Adverse events Mean FCT (h) Mean PCT (h) Cure Last day of observation
Siswantoro et al. MIC + PCR 645 p/µl Chloroquine 25 mg/kg (+150 mg base) Over 3 days 24 48 Y~ 28
Same-Ekobo et al. MIC 534,642 p/µl (total) Artesunate 600 mg Over 5 days Vertigo, non-severe transient decrease of reticulocytes in 1 participant 36.6 38.8 Y 14
Ringwald et al. MIC 2250–40,680 p/µl Pyronaridine 32 mg/kg Over 3 days Mild gastrointestinal disturbances, pruritus 45 57 Y 14
MIC 6656–13,680 p/µl Chloroquine 25 mg/kg Over 3 days 24 60 Y 14
Radloff et al. MIC 700–5000 p/µl Atovaquone/proguanil 3000 mg/1200 mg Over 3 days 72–168 Y 28
Danis et al. Mefloquine 0.5–1.25 mg Once and twice 72–120 Y
  1. MIC microscopy, PCR polymerase chain reaction, Y yes, –not mentioned in the original publication, ~ adequate clinical and parasitological response of P. ovale at day 28, however, reappearing P. vivax in follow up period at days 14 and 23